Additional Countries and rights to commercialize EPI-HNE in the Field of Use *************** outside the Territory *************** Dyax shall grant Debio a *************** to such other countries. Dyax will *************** to Debio of *************** (***************). Debio shall *************** after the *************** during which ***************. If Debio ***************, Dyax shall *************** and to ***************. Before *************** with ***************, Dyax ***************.
Additional Countries. Intact and New Company agree that they will have further discussions in good faith for the opportunity of New Company to market the Product in Vietnam, and Taiwan, or other countries, where Allied has sales channels.
Additional Countries. Should Licensee wish to register the Product for sale in countries other than [*], then [*]. Should licensee wish to register the Product in [*] the parties shall [*].
Additional Countries. KEYSTONE DENTAL will initially have the exclusive license and right to distribute the Licensed Product in the Field of Use in the United States, Canada, Chile and all countries within the European Union. In the case of sales in any other country (other than Korea) where it seeks to register the Licensed Product, KEYSTONE DENTAL shall obtain the exclusive right from NIBEC based on the agreement between NIBEC and KEYSTONE DENTAL as well as subject to the following conditions
Additional Countries. CANADA UNITED STATES (U.S.)
Additional Countries. The parties may, by mutual written agreement, amend Schedule 2 from time to time during the term of this Agreement to add additional countries to the list of Protection Countries as (i) ALRT applies for protection in such additional countries, and (ii) needed by the parties for commercialization of Products. In the event that PARI proposes that one or more countries be added to the list of Protection Countries in Schedule 2 and ALRT fails or refuses to agree to the addition of the country(ies) proposed by PARI within thirty (30) days of its receipt of such proposal, then PARI shall have the right to require ALRT to apply for, seek issuance of, and maintain Patent Rights in such country(ies) at PARI’s expense, and ALRT shall promptly comply with the foregoing. In all cases, the license and rights granted to PARI hereunder shall include the rights to all such additional country(ies).
Additional Countries. Company shall have the right during the Software Period, to notify Cerner in writing of its intent to expand the Territory to Additional Countries. Within ten (10) business days or receipt of such notice, Cerner shall respond in writing indicating either that (a) the Territory has been deemed to be expanded to include the Additional Country or (b) the inclusion of such Additional Country in the Territory at the time of such request would cause Cerner to be in breach of pre-existing contractual commitments (and subject to applicable confidentiality restrictions, Cerner shall inform Company as to the nature of such commitments). If during the Software Period, the Territory is expanded to include Additional Countries, Cerner shall have the option to eliminate any Additional Country from the Territory twenty-four months from the date such Additional Country was included in the Territory if Company fails to enter into a written agreement with another party to deliver Services in such Additional Country during such twenty-four month period.
Additional Countries. Notwithstanding anything in this Agreement to the contrary, the following provisions shall apply solely with respect to Insulet’s activities and planned activities in Austria, Denmark and the Czech Republic (the “Additional Countries”):
Additional Countries. At any time during the term of this Agreement, but in no event before December 1, 2000, if BIOPHARM should not be in violation of any material provision of this Agreement, including without limitation the milestones set forth in Section 4.2, above, BIOPHARM may request from ABI the addition of one or more of the following countries to the Territory: Saudi Arabia, United Arab Emirates, Yemen and Libya. ABI shall honor such request by adding the requested country or countries to the Territory within one (1) year of the receipt of such request in writing, unless ABI shall at any time have received a proposal from another distributor or licensee with terms more favorable to ABI than those set forth in this Agreement; and in such case, ABI shall notify BIOPHARM of all of the material proposed terms and conditions and BIOPHARM shall thereupon have an opportunity to accept such terms and conditions, in which event this Agreement shall be appropriately amended by the parties, in writing. Under no circumstances shall ABI enter into a distribution agreement for the countries of Saudi Arabia, United Arab Emirates,
Additional Countries. If exclusive sublicense rights to the Novartis Patents become available in ******, then MIP shall notify BIOMEDICA in writing of the existence of such rights, and the Parties shall undertake to include ****** within the Territory under this Agreement. Other than ******, if after the Effective Date but within the Term of this Agreement, if MIP desires to sublicense rights to the Novartis Patents for any country not included in the Territory, then MIP shall give BIOMEDICA reasonable notice of its intent and an opportunity to participate in negotiations for sublicense rights in such country.
